Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 10/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431952 | 0.80 | FBP1 (0.62) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL1417534 | 0.80 | FBP1 (0.62) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL7980993 | 0.78 | FBP1 (0.60) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL7981278 | 0.78 | FBP1 (0.60) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL31745276 | 0.78 | FBP1 (0.57) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL31745150 | 0.77 | FBP1 (0.59) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL2423336 | 0.77 | FBP1 (0.69) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL21188250 | 0.72 | FBP1 (0.53) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL1417870 | 0.71 | PPARA (0.71) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL9234505 | 0.71 | CES2 (0.43) | FBP1TSHRMAPTHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667461-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON S AND GAUCHER DISEASE | Children's Hospital Medical Center (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | CHILDRENS HOSPITAL MED CT (US) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | GBA1, GAA, GBA2 | FBP1 1165/4885PPARA 1402/4885ABCB11 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.